Skip to content
Life Sciences Series A Founded 2010

ZielBio

Developer of targeted therapeutics for cancer. The company uses ZielFind, a target discovery platform to discover new targets. The company's lead molecules, ZB131 fMAb & ZB220 ADC are being developed to target cell surface cytolinker proteins, Plectin-1 as anticancer drugs. The company is also discovering novel cell targets for cardiology, neurology & metabolic diseases with other partners. The company was founded…

📍 Charlottesville, United States · Genomics,

Funding snapshot

Last roundSeries A
Amount$25M
Date25 September 2019
Total raised$26M
Team size9

About

Developer of targeted therapeutics for cancer. The company uses ZielFind, a target discovery platform to discover new targets. The company's lead molecules, ZB131 fMAb & ZB220 ADC are being developed to target cell surface cytolinker proteins, Plectin-1 as anticancer drugs. The company is also discovering novel cell targets for cardiology, neurology & metabolic diseases with other partners. The company was founded in 2010 and headquartered in Charlottesville, United States. It has raised $26.3M in series a funding, with backing from Center for Innovative Technology, 5Y Capital, Partners Health Care Innovation, Morningside, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Immunotherapy, HealthTech - Life Sciences Tech space. Its offerings span Oncology - Drugs - Diversified.

Business model

Life Sciences Tech > Research & Development > Drug Discovery > Proteomics,

Oncology > Drugs > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Center for Innovative Technology 5Y Capital Partners Health Care Innovation Morningside HHS Mass General Brigham Ventures

Latest coverage

No articles yet.

Raising like ZielBio?

Analyze your pitch deck before your next raise.

Analyze My Deck →